Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Drug attack on Hard-to-Treat myeloma enters early human tests

NCT ID NCT07280013

Disease control Sponsor: C4 Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers will also check whether the drugs shrink tumors. Participants will take cemsidomide for two weeks on and two weeks off, plus elranatamab injections twice a month.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cemsidomide (oral drug) and elranatamab (injectable antibody)
What this could lead to
If this works, it could offer a new treatment option for people with multiple myeloma that has come back after other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 60 people. The main goal is safety, not proof of effectiveness. Side effects or lack of response are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of multiple myeloma as defined by IMWG criteria * Measurable disease based on IMWG criteria * Received 2-4 prior lines of therapy (escalation part) and 1-3 prior lines of therapy (expansion part) for multiple myeloma, consisting of at least 1 immunomodulatory drug (i.e., IKZF 1/3 degrader) * ECOG performance status 0-2 Exclusion Criteria: * Active plasma cell leukemia, Smoldering multiple myeloma, POEMS Syndrome, systemic light chain amyloidosis, MDS * Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease * Participants with any active, uncontrolled bacterial, fungal, or viral infection * Prior treatment with a BCMA-directed TCE or BCMA-directed CAR-T therapy * Administration with an investigational product within 30 days preceding the first dose of study intervention * Inability or difficulty swallowing tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma (MM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bites and Stings plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma (MM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    20 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Banner MD Anderson Cancer Center

    RECRUITING

    Gilbert, Arizona, 85234, United States

  • Baylor University Medical Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75246, United States

  • Dartmouth-Hitchcock Medical Center

    NOT_YET_RECRUITING

    Lebanon, New Hampshire, 03756, United States

  • Duke Cancer Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Houston Methodist Hospital

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Huntsman Cancer Institute, University of Utah

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Indiana University

    NOT_YET_RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Loyola University Medical Center

    NOT_YET_RECRUITING

    Maywood, Illinois, 60153, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

  • Norton Cancer Institute St. Matthews

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • Ohio State University Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

  • Perlmutter Cancer Center at NYU Langone Hospital

    RECRUITING

    Brooklyn, New York, 11203, United States

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • UC Davis Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Sacramento, California, 95817, United States

  • UCLA Health, Jonsson Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Santa Monica, California, 90404, United States

  • University of Florida

    NOT_YET_RECRUITING

    Gainesville, Florida, 32610, United States

  • University of Maryland Greenbaum Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • University of Miami

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

  • University of Nebraska

    NOT_YET_RECRUITING

    Omaha, Nebraska, 68105, United States

  • Winship Cancer Institute, Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.